Table 4.
The pooled associations between different subgroups and prognosis of patients with NSCLC.
| Subgroup | Number of patients | Number of studies | HR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I-square | P | |||||
| Overall effect | 5553 | 32 | 1.59 (1.39–1.82) | <0.001 | 84.97% | <0.001 |
| MicroRNAs | ||||||
| miR-21 | 2025 | 10 | 1.95 (1.40–2.72) | <0.001 | 88.05% | <0.001 |
| miR-155 | 2047 | 9 | 1.33 (0.87–2.04) | <0.001 | 73.27% | <0.001 |
| miR-let-7 | 1239 | 4 | 1.94 (0.87–4.32) | 0.101 | 87.59% | <0.001 |
| miR-148a | 377 | 2 | 2.33 (0.80–6.71) | 0.117 | 57.92% | 0.123 |
| miR-148b | 380 | 2 | 2.28 (1.64–3.17) | <0.001 | 0.00 | 0.749 |
| miRNA assay method | ||||||
| ISH | 750 | 4 | 1.05 (0.58–1.87) | 0.870 | 75.51% | 0.007 |
| Microarray/qRT-PCR | 4803 | 28 | 1.63 (1.42–1.87) | <0.001 | 85.49% | <0.001 |
| Analysis type | ||||||
| Multivariate | 4785 | 28 | 1.54 (1.35–1.76) | <0.001 | 84.81% | <0.001 |
| Univariate | 768 | 4 | 2.29 (1.02–5.12) | 0.043 | 72.34% | 0.013 |
| Source of miRNA | ||||||
| Paired Tissue | 3999 | 20 | 1.67 (1.39–1.99) | <0.001 | 83.98% | <0.001 |
| Blood | 611 | 4 | 1.73 (1.13–2.65) | 0.012 | 68.02% | 0.025 |
| Patient origin | ||||||
| Asia | 3432 | 20 | 2.05 (1.66–2.53) | <0.001 | 78.85% | <0.001 |
| Europe | 662 | 6 | 1.24 (1.05–1.47) | 0.011 | 61.28% | 0.006 |
| USA | 1439 | 6 | 2.26 (1.81–2.83) | <0.001 | 0.00 | 0.946 |
ISH: in situ hybridization; qRT-PCR: quantitative real-time polymerase chain reaction; HR: hazard ratio; CI: confidence intervals.